相似文献
1
Pegylated arginine deiminase: a novel anticancer enzyme agent.
Expert Opin Investig Drugs. 2006 Jul;15(7):815-22. doi: 10.1517/13543784.15.7.815.
2
Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Cancer Res. 2002 Oct 1;62(19):5443-50.
3
Arginine deprivation as a targeted therapy for cancer.
Curr Pharm Des. 2008;14(11):1049-57. doi: 10.2174/138161208784246199.
4
Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Oncotarget. 2010 Aug;1(4):246-51. doi: 10.18632/oncotarget.135.
5
The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
Int J Mol Sci. 2017 Jun 1;18(6):1175. doi: 10.3390/ijms18061175.
6
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Br J Cancer. 2012 Apr 24;106(9):1481-5. doi: 10.1038/bjc.2012.106.
7
Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
Oncotarget. 2015 Mar 20;6(8):6295-309. doi: 10.18632/oncotarget.3370.
8
Amino Acids Sequence-based Analysis of Arginine Deiminase from Different Prokaryotic Organisms: An In Silico Approach.
Recent Pat Biotechnol. 2020;14(3):235-246. doi: 10.2174/1872208314666200324114441.
9
Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
BMC Cancer. 2014 Aug 28;14:621. doi: 10.1186/1471-2407-14-621.
10
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
Cancer Res. 2012 May 15;72(10):2622-33. doi: 10.1158/0008-5472.CAN-11-3605. Epub 2012 Mar 29.
引用本文的文献
1
Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma.
Gastroenterol Hepatol (N Y). 2025 May;21(5):286-297.
2
[Aggressive variant prostate cancer and transdifferentiated neuroendocrine prostate cancer: from diagnosis to therapy].
Urologie. 2025 Mar;64(3):246-255. doi: 10.1007/s00120-024-02511-3. Epub 2025 Feb 10.
3
Metabolic-Modulating Effects of Radiation: Undetectable Yet Deadly-A Review on Radiotherapy.
Cancers (Basel). 2024 Dec 27;17(1):54. doi: 10.3390/cancers17010054.
4
Stability of immobilized L-arginine deiminase from Penicillium chrysogenum and evaluation of its anticancer activity.
Sci Rep. 2024 Nov 8;14(1):27216. doi: 10.1038/s41598-024-77795-8.
5
Characterization, modeling, and anticancer activity of L.arginase production from marine Bacillus licheniformis OF2.
BMC Biotechnol. 2024 Jan 25;24(1):6. doi: 10.1186/s12896-024-00829-6.
6
PEGylated therapeutics in the clinic.
Bioeng Transl Med. 2023 Sep 22;9(1):e10600. doi: 10.1002/btm2.10600. eCollection 2024 Jan.
7
A metabolic perspective on nitric oxide function in melanoma.
Biochim Biophys Acta Rev Cancer. 2024 Jan;1879(1):189038. doi: 10.1016/j.bbcan.2023.189038. Epub 2023 Dec 5.
8
Recent advances in glucose oxidase-based nanocarriers for tumor targeting therapy.
Heliyon. 2023 Sep 25;9(10):e20407. doi: 10.1016/j.heliyon.2023.e20407. eCollection 2023 Oct.
9
Human arginase I: a potential broad-spectrum anti-cancer agent.
3 Biotech. 2023 May;13(5):159. doi: 10.1007/s13205-023-03590-3. Epub 2023 May 3.
10
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Pharmacol Rep. 2023 Jun;75(3):570-584. doi: 10.1007/s43440-023-00480-6. Epub 2023 Apr 3.
本文引用的文献
1
Amino acid requirements of man.
Fed Proc. 1949 Jun;8(2):546-52.
2
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.
Clin Cancer Res. 2006 Dec 1;12(23):7126-31. doi: 10.1158/1078-0432.CCR-06-1101.
3
Identification of differentially expressed genes in clear cell renal cell carcinoma by analysis of full-length enriched cDNA library.
J Biomed Sci. 2006 Mar;13(2):233-40. doi: 10.1007/s11373-005-9059-1.
4
Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase.
Cancer Lett. 2006 Jan 8;231(1):30-5. doi: 10.1016/j.canlet.2005.01.007.
5
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
J Clin Oncol. 2005 Oct 20;23(30):7660-8. doi: 10.1200/JCO.2005.02.0933.
6
Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells.
Semin Cancer Biol. 2005 Aug;15(4):247-53. doi: 10.1016/j.semcancer.2005.04.002.
7
Updated treatment approach to hepatocellular carcinoma.
J Gastroenterol. 2005 Mar;40(3):225-35. doi: 10.1007/s00535-005-1566-3.
8
Controlling cancer by restricting arginine availability--arginine-catabolizing enzymes as anticancer agents.
Anticancer Drugs. 2004 Oct;15(9):825-33. doi: 10.1097/00001813-200410000-00002.
9
Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells.
Int J Cancer. 2004 Nov 10;112(3):502-8. doi: 10.1002/ijc.20435.
10
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
J Clin Oncol. 2004 May 15;22(10):1815-22. doi: 10.1200/JCO.2004.11.120.
Zotero 插件